Technology Catalysts has been interviewed and/or featured in a number of published articles over the years. To view these articles and other TCI press releases, please select a document from the list below:
May 01, 2015
Spurred by strong public interest, the FDA is actively reviewing guidance on the need for abuse deterrent formulations. The FDA is currently working on a case-by-case basis to determine whether or not opioid based formulations should only receive approval if they possess abuse deterrent properties.
July 01, 2014
Poor bioavailability is a major reason for compounds to fail in preclinical development. Technology Catalysts International (TCI) has compiled and analyzed technical and market information pertaining to the delivery of poorly water soluble or poorly permeable pharmaceutical compounds.
July 01, 2013
Consumer and scientific interest in the relationship between diet, health, and alternative medicines has created an increased demand for medical and modified functional foods. Sparked by rising interest in attaining wellness through diet, factors such as rapid advances in science and technology, increasing healthcare costs, changes in food labeling and claim regulations, and aging populations, have fueled the growth of both markets.
April 01, 2013
Orally disintegrating tablets (ODTs) are coming into their own as mainstream pharmaceutical products. Oral thin films (OTFs) have also come into strong prominence with the launch of Suboxone® (buprenorphine and naloxone) thin films demonstrating a huge potential for thin films in prescription products.
March 01, 2013
Emerging opportunities in drug device combinations to address the critical needs of the rapidly growing biologics market for patient friendly administration.
April 01, 2011
March 01, 2011
Emerging opportunities in probiotics to address oral, women's, and additional digestive healthcare to greatly increase the market for probiotic strains.
February 01, 2011